Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur (9)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Article : Périodique
J. REHM ; M. X. REHM ; H. ALHO ; A. ALLAMANI ; H. J. AUBIN ; G. BÜHRINGER ; J. B. DAEPPEN ; U. FRICK ; A. GUAL ; N. HEATHER |Aim: To describe guidelines and common practices for alcohol dependence treatment in Europe. Design: Systematic and qualitative review; for each country, guidelines were identified via systematic literature research, followed by interviews with[...]
Périodique
M. AALTO ; SEPPÄ K. ; P. MATTILA ; MUSTONEN H. ; RUUTH K. ; HYVÄRINEN H. ; PULKKINEN H. ; H. ALHO ; SILLANAUKEE P. | 2001ENGLISH : The aim of this research was to evaluate the effectiveness of long- term brief intervention in routine general practice. In five primary care out-patient clinics in a Finnish town, 296 male early-phase heavy drinkers consulting a gen[...]
Article : Périodique
E. LAUNONEN ; H. ALHO ; E. KOTOVIRTA ; I. WALLACE ; K. SIMOJOKI |Background: Diversion (i.e. selling or giving away) of opioid maintenance treatment (OMT) medications is a challenge that concerns many units providing OMT worldwide and tools for prevention are needed. The object of this study was to examine th[...]
Périodique
RAPELI P. ; FABRITIUS C. ; H. ALHO ; SALASPURO M. ; WAHLBECK K. ; KALSKA H. | 2007ENGLISH : BACKGROUND: Both methadone- and buprenorphine-treated opioid-dependent patients frequently show cognitive deficits in attention, working memory, and verbal memory. However, no study has compared these patient groups with each other d[...]
Article : Périodique
H. ALHO ; M. DEMATTEIS ; D. LEMBO ; I. MAREMMANI ; C. RONCERO ; L. SOMAINI |Use of illicit opioids and misuse of prescription opioids are the main causes of drug-related deaths across the world, and the continuing rise in opioid-related mortality, especially affecting North America, Australia and Europe, is a public hea[...]
Article : Périodique
M. DEMATTEIS ; M. AURIACOMBE ; O. D'AGNONE ; L. SOMAINI ; N. SZERMAN ; R. LITTLEWOOD ; F. ALAM ; H. ALHO ; A. BENYAMINA ; J. BOBES ; J. P. DAULOUEDE ; C. LEONARDI ; I. MAREMMANI ; M. TORRENS ; S. WALCHER ; M. SOYKA |FRANÇAIS : Introduction : La prise en charge des patients souffrant d'un trouble de l'usage des opioïdes (TUO) comprend généralement un traitement par agoniste opioïdergique (TAO) dans le cadre d'un plan de traitement intégré. Ces interventions[...]
Article : Périodique
Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus
M. DEMATTEIS ; M. AURIACOMBE ; O. D'AGNONE ; L. SOMAINI ; N. SZERMAN ; R. LITTLEWOOD ; F. ALAM ; H. ALHO ; A. BENYAMINA ; J. BOBES ; J. P. DAULOUEDE ; C. LEONARDI ; I. MAREMMANI ; M. TORRENS ; S. WALCHER ; M. SOYKA |Introduction: Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society. [...]![Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs [Commentary]](https://bdoc.ofdt.fr/img_cache/5b2fc2911f196cb9326a86c7de9e7b4f.png)
Article : Périodique
J. GREBELY ; J. BRUNEAU ; J. V. LAZARUS ; O. DALGARD ; P. BRUGGMANN ; C. TRELOAR ; M. HICKMAN ; M. HELLARD ; T. ROBERTS ; L. CROOKS ; H. MIDGARD ; S. LARNEY ; L. DEGENHARDT ; H. ALHO ; J. BYRNE ; J. F. DILLON ; J. J. FELD ; G. FOSTER ; D. GOLDBERG ; A. R. LLOYD ; J. REIMER ; G. ROBAEYS ; M. TORRENS ; N. WRIGHT ; I. MAREMMANI ; B. L. NORTON ; A. H. LITWIN ; G. J. DORE ; International Network on Hepatitis in Substance Users |Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among th[...]Nouveauté
Article : Périodique
SIMOJOKI K. ; H. VORMA ; H. ALHO |BACKGROUND: In Finland, buprenorphine (Subutex) is the most abused opioid. In order to curb this problem, many treatment centres transferred (forced transfer) their buprenorphine patients to the buprenorphine plus naloxone (Suboxone) combination[...]
